Skin Cancer & Melanoma

Latest News

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.
Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

July 22nd 2025

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

The FDA indicated that data from the phase 1/2 IGNYTE trial were not adequate to provide evidence of effectiveness.
FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma

July 22nd 2025

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.
Nivolumab Plus Relatlimab Shows Long-Term EFS Benefit in Advanced Melanoma

July 14th 2025

ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.
Advancing Treatment for EGFR Inhibitor–Associated Dermal Toxicities

July 8th 2025

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

June 12th 2025

Video Series
Video Interviews
Podcasts
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

More News